Hexarelin
Also known as: Examorelin
Hexarelin is a synthetic growth hormone releasing peptide and ghrelin-mimetic studied in early research for its reported ability to stimulate growth hormone release. It is not approved for human use in Australia.
- Category
- Growth Hormone Secretagogue
- Reported half-life
- Reported ~55-70 minutes (varies by study)
- Common forms
- Lyophilised powder for reconstitution, Injectable solution
- Research status
- Not approved for human use in Australia; investigated in early clinical and preclinical research only, including cardiovascular studies. No marketed human therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to stimulate a strong pulse of growth hormone release
- Early research indicates possible cardiovascular effects independent of growth hormone
- Users report interest in recovery and body composition
- Reported tendency toward receptor desensitisation with repeated exposure in some studies
How it is reported to work
Hexarelin is reported to mimic ghrelin and bind the growth hormone secretagogue receptor, prompting the pituitary to release growth hormone. Some research also describes interactions with the CD36 receptor that are proposed to underlie reported cardiovascular effects independent of growth hormone. These mechanisms come from early and animal research and are not established for general human use.
Background
Hexarelin (examorelin) is a synthetic growth hormone releasing peptide - a ghrelin-mimetic reported to be among the more potent growth hormone stimulators in its class. It has also drawn research interest for reported cardiovascular effects that may be partly independent of growth hormone. This page is educational information, not medical advice.
What the research actually shows
Hexarelin has been examined in early-stage and animal research, where it is reported to trigger strong growth hormone release and to interact with cardiac receptors. Some studies also report receptor desensitisation with repeated exposure. Large, long-term human clinical trials are not available.
| Evidence type | Status |
|---|---|
| Early/animal research | Present |
| Large human trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report using hexarelin in attempts to support recovery and body composition. These are anecdotal reports, not validated clinical results. Studies suggest mechanisms involving the growth hormone secretagogue and CD36 receptors, but reported benefits should not be read as established facts.
Things to be aware of
Hexarelin is not approved for human use in Australia. Potent growth hormone and possible cardiovascular effects can have unintended consequences, and grey-market product purity cannot be verified by sight.
If you have a health concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article is not an endorsement and does not recommend obtaining or using hexarelin.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to stimulate a strong pulse of growth-hormone release
- Reported among the more potent growth-hormone stimulators in its class
- Reported possible cardiovascular effects independent of growth hormone
- Users report interest in recovery and body composition
- Reported milder appetite stimulation than GHRP-6
Common side effects
- Injection-site reactions such as redness or itching
- Facial flushing or head-rush after injection
- Water retention or puffiness
- Tingling or numbness in the hands
- Tiredness or drowsiness
Rare / serious side effects
- Raised prolactin or cortisol reported at higher doses in some studies
- Changes in blood-sugar control
- Allergic-type reactions
- Reactions attributed to impurities in unregulated grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Hexarelin. Listed so you can make an informed decision, not to suggest any use is safe.
- Hexarelin is reported to cause receptor desensitisation with repeated or prolonged use, so overuse is reported to make it progressively less effective and to risk blunting the body's own growth-hormone response
- Chronic high-dose use is reported to risk suppressing natural pulsatile growth-hormone production
- Higher doses are reported to raise prolactin and cortisol, a frequently cited reason against overuse
- Sustained growth-hormone and IGF-1 elevation from overuse is reported to risk insulin resistance, fluid retention and theoretical concern about abnormal tissue growth
- Unverified grey-market product is reported to risk contamination and incorrect dosing
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Early sleep and recovery changes are often reported within days, though effects are reported to plateau over time as receptors desensitise with continued use.
First effects
Sleep and recovery changes within days
Noticeable change
Recovery and well-being ~4 weeks
Clear results
Body-composition changes ~12 weeks
Peak effect
Effects reported to plateau as receptors desensitise
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Hexarelin. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Reported community figures of roughly 100 mcg per dose |
| Frequency | Reported as 1–3× daily, with reported receptor desensitisation noted with continuous use (users report keeping doses and duration limited) |
| Cycle length | Reported short cycles of about 4–6 weeks, then a break, due to reported desensitisation |
Reported reconstitution (mg → units)
Worked example only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 100 mcg (0.1 mg) dose ≈ 0.04 mL = 4 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorCommonly reported community patterns describe short cycles, with users reporting deliberate breaks because of its reported tendency to desensitise receptors faster than other secretagogues. Daily dosing over a few weeks followed by time off is commonly reported. These are reported patterns only, not a recommendation, and hexarelin is not approved for human use in Australia.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported pairing of a ghrelin-mimetic with a GHRH analogue to amplify the growth-hormone pulse
Reported as a milder ghrelin-mimetic users rotate to in order to limit desensitisation
Discussed alongside as a comparison within the same peptide class
Safety notes
Hexarelin is not approved by the TGA for human use in Australia, and long-term human safety data is lacking. Potent growth hormone and possible cardiovascular effects can carry risks, and grey-market product purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.